Mobile

PHASE 2 STUDY OF SINGLE-AGENT PF 03084014 IN PATIENTS WITH ADVANCED TRIPLE-NEGATIVE BREAST CANCER WITH OR WITHOUT GENOMIC ALTERATIONS IN NOTCH RECEPTORS

Mise à jour : Il y a 4 ans
Référence : EUCTR2014-002286-30

Femme Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

•To estimate the objective response rate (ORR) of PF-03084014 when given as a single agent in the treatment of patients with advanced TNBC harboring genomic alterations in Notch receptors (NA+).

Critère d'inclusion

  • ADVANCED TRIPLE-NEGATIVE BREAST CANCER WITH OR WITHOUT GENOMIC ALTERATIONS IN NOTCH RECEPTORS

Liens